Although 68Ga-PSMA PET/CT is a technique that has only recentlybeen applied in clinical settings, despite its high cost,68Ga-PSMA PET/CT shows great promise as a tool in the clinicalmanagement of patients with kidney and prostate cancer, especially in thosewith prostate cancer whose PSA levels are elevated even after treatment. This evidence concerns the gene KLK3 and Familial prostate cancer.